Coagulant Therapeutics Venture Capital
2 known investors
Coagulant Therapeutics is a biopharmaceutical company, formed in 2019, developing biologics with a focus on hematology and coagulation-related therapeutics.
Also known as Coagulant Therapeutics · Coagulant Therapeutics Corporation
Founders & leadership
Investors · 2
Company profile
researched Aug 2026Coagulant Therapeutics Corporation is a privately held biopharmaceutical company based in Berkeley, California, focused on the design, development and commercialization of therapeutics directed at the coagulation cascade and adjacent biology. Its stated target indications fall under acute bleeding, including severe postpartum hemorrhage, intracranial hemorrhage, traumatic brain injury and trauma, areas the company describes as having no approved pharmaceutical treatments.
The lead product candidate is CT-001, a next-generation recombinant Factor VIIa engineered both to increase hemostatic potency and to incorporate additional safety features, in development for severe postpartum hemorrhage. Alongside CT-001, the company runs research programs on antibodies targeting activated protein C (APC), a pleiotropic protease with anticoagulant and anti-inflammatory activity. These programs include a proprietary llama-derived nanobody library directed at non-active sites of APC, which produced a lead being studied in trauma and hemophilia, and a directed-evolution campaign on a known APC antibody, TPP-26870, which yielded single amino acid variants with divergent activity profiles. Together these assets form a pipeline aimed at acute bleeding, sepsis, hemophilia and ischemia.
Founding story
Coagulant Therapeutics was founded in 2019 by Terry Hermiston, PhD, who serves as Chief Executive Officer and Founder. The company built its initial asset base around intellectual property and molecules originating outside the company, including over 30 patents acquired from Bayer AG and Maxygen, and states that CT-001 is licensed from Bayer AG.
Traction
Preclinical and research-stage progress reported through peer-reviewed publications, including a 2023 Blood Advances paper on a nanobody-derived APC antibody library and a January 2025 Blood Advances publication on directed-evolution APC antibody variants, generated in a company-sponsored study conducted with Laurent Mosnier, PhD, of The Scripps Research Institute.
Latest developments
In January 2025 the company announced the online publication of "Divergent modulation of activated protein C pleiotropic functions by antibodies that differ by a single amino acid" in Blood Advances, and separately announced that CEO and founder Terry Hermiston would present at Biotech Showcase 2025.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
The company positions itself as a developer of therapies for acute bleeding, a setting it describes as lacking approved pharmaceutical treatments, and claims a leadership position in developing APC-based treatments.
Coagulant cites an in-licensed and acquired IP base of more than 30 patents from Bayer AG and Maxygen, a proprietary engineered rFVIIa (CT-001) balancing potency with engineered safety, and two independently generated proprietary APC antibody libraries producing differentiated molecules.
Technology
The company's approach combines expertise in the coagulation cascade with protein and antibody engineering. CT-001 is a proprietary, optimized recombinant Factor VIIa molecule engineered to enhance activity while adding safety measures. The APC programs use llama-derived nanobodies raised against non-active-site epitopes of activated protein C, and directed evolution applied to the parental antibody TPP-26870 to generate single amino acid variants that selectively modulate APC's anticoagulant versus anti-inflammatory functions. One variant, an N57W VL substitution, showed prolonged APC in vitro plasma half-life, enhanced anticoagulant activity and histone cleavage, characteristics the company links to potential treatment of trauma-induced coagulopathy.
Go-to-market
The company engages investors and potential partners through industry conferences and scientific channels, including a presentation at Biotech Showcase 2025 and an oral presentation at the 2024 ISTH Congress, and states it is working with current and future investors to advance its acute bleeding programs.
Patients with acute bleeding conditions, including severe postpartum hemorrhage, trauma, traumatic brain injury and intracranial hemorrhage, and potentially hemophilia, sepsis and ischemia.
Geography
Headquartered in Berkeley, California.
History
Since its 2019 founding, the company has advanced CT-001 toward severe postpartum hemorrhage and built out APC-directed antibody programs. It announced an oral presentation at the 2024 International Society for Thrombosis and Haemostasis (ISTH) Congress in April 2024, and in January 2025 both presented at the Biotech Showcase 2025 investor conference and announced publication of an APC antibody manuscript in the American Society of Hematology journal Blood Advances. Earlier nanobody-derived antibody work was published in Blood Advances in 2023.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsCoagulant announced online publication of "Divergent modulation of activated protein C pleiotropic functions by antibodies that differ by a single amino acid" in Blood Advances, from a company-sponsored study with Laurent Mosnier of The Scripps Research Institute.
CEO and founder Terry Hermiston presented the company at the Biotech Showcase 2025 investor conference.
The company announced an upcoming oral presentation at the 2024 International Society for Thrombosis and Hemostasis Congress.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 2
primary sources listed
- Coagulant Therapeutics Venture Capitalcoagulanttherapeutics.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Coagulant Therapeutics Venture Capital do?
- Berkeley-based biopharmaceutical company developing engineered Factor VIIa and APC-targeted antibodies for acute bleeding.
- Who founded Coagulant Therapeutics Venture Capital?
- Coagulant Therapeutics Venture Capital was founded by Terry Hermiston.
- Who are Coagulant Therapeutics Venture Capital's investors?
- Coagulant Therapeutics Venture Capital's investors include Colopl Next, IMM Investment Japan.